Work

Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy

Year: 2026

Type: review

Abstract: Background: Relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL) has poor outcomes and limited salvage options. Objectives: To evaluate the efficacy and safety of daratumumab-based therapy in R/R T-ALL/T-LBL. Design: Systematic review of observational reports. Methods: Sixteen reports including 34 patients treated with daratumumab-based regimens were reviewed. Baseline characteristics, treatment patterns, response, MRD status, survival, allogeneic HSCT, and safety were descriptively synthesized. Results: Complete remission was reported in 30/34 patients (88.2%), partial remission in 2/34 (5.9%), and no response in 2/34 (5.9%). Among complete responders with reported MRD status, 24/29 (82.8%) achieved MRD negativity. Median PFS was 10 months (range, 0.4-45), and median OS was 10 months (range, 1.5-45), although many values reflected last follow-up. Eighteen patients (52.9%) proceeded to allogeneic HSCT; 13/18 (72.2%) were alive at last follow-up. Infusion reactions occurred in 10 patients, mostly grade 1-2. Conclusion: Daratumumab-based therapy may induce remission and facilitate HSCT bridging in selected patients, but findings remain hypothesis-generating because evidence is mainly from case reports and small series.

Source: Therapeutic Advances in Hematology

DOI: 10.1177/20406207261484097

Authors: Abdulrahman F. Al-Mashdali, Mujahid O. Abdelraof, Monia Ibrahim, Mohammed Abdulgayoom, Shehab F. Mohamed, Honar Cherif

Institutions: National Center for Cancer Care and Research, Hamad Medical Corporation, University of Gezira

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,650